Pulmatrix Inc
NASDAQ:PULM

Watchlist Manager
Pulmatrix Inc Logo
Pulmatrix Inc
NASDAQ:PULM
Watchlist
Price: 2.47 USD 4.22% Market Closed
Market Cap: 9m USD

Net Margin
Pulmatrix Inc

-207 333.3%
Current
-16 326%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-207 333.3%
=
Net Income
-6.2m
/
Revenue
3k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Pulmatrix Inc
NASDAQ:PULM
9m USD
-207 333%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
496.3B USD
27%
CH
Roche Holding AG
SIX:ROG
262.9B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
16%
CH
Novartis AG
SIX:NOVN
212.1B CHF
26%
US
Merck & Co Inc
NYSE:MRK
260.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
143B USD
16%
No Stocks Found

Pulmatrix Inc
Glance View

Market Cap
9m USD
Industry
Pharmaceuticals

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2014-03-21. The company designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.

PULM Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-207 333.3%
=
Net Income
-6.2m
/
Revenue
3k
What is the Net Margin of Pulmatrix Inc?

Based on Pulmatrix Inc's most recent financial statements, the company has Net Margin of -207 333.3%.

Back to Top